Vertex Pharmaceuticals (VRTX) pointed to an expanding renal pipeline as a defining growth pillar during the Wells Fargo 21st Annual Healthcare Conference, held September 8–10, where executives discussed commercial momentum, clinical catalysts and the recent Crinetics acquisition.
Vertex trades at roughly $521, near its 52-week high of $560, with a P/E of 30.3. The company carries a market capitalization of about $134 billion and generated $12.6 billion in trailing-twelve-month revenue, up 10%, while maintaining a 24% return on equity. Analyst Mohit Bansal of Wells Fargo covered the session alongside Vertex investor-relations executives Susie Lisa and Manisha Pai.
Lisa described the current stage of the renal franchise as a "renal renaissance." The pipeline includes povetacicept (pove) for IgA nephropathy and inaxaplin for APOL1-mediated kidney disease (AMKD), which encompasses focal segmental glomerulosclerosis (FSGS). Earlier Phase II data in FSGS showed a 47.6% reduction in proteinuria at 13 weeks, with APOL1 inhibition confirmed at more than 98%. The AMPLITUDE Phase III study is targeting about 150,000 patients in the U.S. and Europe, with expansion cohorts that could add another 100,000; enrollment is expected to close by end-2024.
Inaxaplin's moderate-proteinuria cohort starts at a baseline near 0.3 or lower, compared with 0.7 to 0.8 in the FSGS population. Interim data from the primary AMKD population are targeted for Q1 2027, looking at eGFR change from baseline and proteinuria reduction at 48 weeks. Lisa noted that AMKD patients lose eGFR roughly twice as fast as typical chronic kidney disease patients — 6 to 7 points annually versus 3 to 4.
Povetacicept, delivered via a low-volume 0.46 ml auto-injector, has interim data showing a 42% reduction in UPCR. The U.S. biopsy-confirmed IgAN population is estimated at about 160,000. The PDUFA date for povetacicept in IgA nephropathy is November 30, 2024. A potential second renal launch, contingent on positive AMPLITUDE interim data, is being considered for around September 2027.
On the commercial side, JOURNAVX prescriptions are tracked to triple in 2026 versus 2025, supported by more than 36,000 prescribers across emergency rooms, trauma, orthopedics, dentistry and related specialties. Hospital and retail scripts are splitting roughly 50/50 — above the market baseline of one-third hospital and two-thirds retail — with hospital runs averaging two to five days and retail scripts running about 14 days on average. Vertex expects JOURNAVX gross-to-net to normalize to the mid-50% range by mid-2027, plus or minus 50 percentage points.
Vertex also projects combined peak sales of approximately $5 billion for PALSONIFY and atumelnant, the latter a drug for congenital adrenal hyperplasia and Cushing's disease. The company's next-generation cystic fibrosis candidate VX-522 and myotonic dystrophy type 1 data are both due by end-2024, along with completion of enrollment in two diabetic peripheral neuropathy Phase III studies that showed more than a 2-point improvement on the Numeric Pain Rating Scale in Phase II. A Myasthenia Gravis Phase II study is underway in about 30 patients across placebo and two treatment arms over 12 weeks, representing what Lisa called the "poster child" for B-cell mediated disease.
